patientes with CONgestive heart failure benefit for long-TErm treatment effects with New Treatment using azosemide compared with furosemide derived from Existing retrospective study Data
- Conditions
- Patients with moderate congestive heart failure
- Registration Number
- JPRN-UMIN000021994
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
Patients who fall into any of the following criteria before discharge (from hospital) are excluded. The value "before discharge" means the last value collected before the patient leaves the hospital. 1. Blood glucose is inadequately controlled (hemoglobinA1c is over 9%, or over 200mg/dl at fasting state) 2. Symptomatic hypoglycemia 3. Inadequately controlled blood glucose with systolic blood pressure over 180mmHg 4. Serum Cr is over 2.5 mg/dl 5. Severe liver impairment, or any other acute and life-threating impairment 6. Has artificial auxiliary heart implanted 7. Complicated with severe chronic obstructive pulmonary disease or locality lung disease 8. Neither primary pulmonary hypertension nor left ventricular impairment is the cause of current pulmonary hypertension 9. Patients with acute coronary syndrome or cerebrovascular impairment, or underwent PCI or thoracotomy for cardiac surgery within last three months before hospitalization due to heart failure 10. Patients underwent treatment of cardiac resynchronization therapy, intraaortic balloon pumping, left ventricular assist device, or heart transplant due to heart failure 11. Severe cerebrovascular impairment 12. One type of loop diuretics other than azosemide or furosemide is prescribed 13. Currently using tolvaptan (Patients who temporally used tolvaptan during hospitalization can be enrolled) 14. Anyone who refuses to have their information used in this study 15. Patients need certain amount of azosemide or furosemide that is beyond health insurance coverage 16. Anyone with a condition judged by the physician (investigator) to be inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of "Cardiovascular death + Hospitalization for heart failure"
- Secondary Outcome Measures
Name Time Method Secondary outcomes are chosen based on J-MELODIC: * Incidences of "cardiovascular death", "hospitalization for heart failure" and "death caused by other reasons" * Change in CTR * Change in BNP * Change in LVEF (calculated based on the modified Simpson's rule) * Change in severity of heart failure (NYHA classification) * Change in other measured values